BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, November 14, 2025
See today's BioWorld MedTech
Home
» A royalty pain: Zimmer liable for payments despite patent expiry
To read the full story,
subscribe
or
sign in
.
A royalty pain: Zimmer liable for payments despite patent expiry
July 22, 2024
By
Mark McCarty
Royalties for licensed patents ordinarily need not be paid after the underlying patent has expired, but the case of
Zimmer Biomet Holdings Inc. v. Insall
would seem to throw out a cautionary flag regarding such agreements.
BioWorld MedTech
Regulatory
Orthopedics
U.S.